Drug Profile
SCO 201
Alternative Names: SCO-201Latest Information Update: 28 Jan 2023
Price :
$50
*
At a glance
- Originator German Dritte Patent Portfolio Beteiligungsgesellschaft
- Developer Scandion Oncology
- Class Amines; Aniline compounds; Antineoplastics; Pyrazoles; Pyrimidines; Small molecules
- Mechanism of Action ATP-binding cassette transporter modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Jan 2023 No recent reports of development identified for preclinical development in Solid-tumours in Denmark (PO)
- 21 Dec 2018 Preclinical trials in Solid tumours in Denmark (unspecified route) before December 2018 (Scandion Oncology pipeline - December 2018)